Zhaoke Ophthalmology Limited (HKG:6622)

Market Cap	1.46B
Revenue (ttm)	73.77M
Net Income (ttm)	-252.73M
Shares Out	546.14M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,783,552
Average Volume	2,345,453
Open	2.620
Previous Close	2.620
Day's Range	2.620 - 2.750
52-Week Range	1.200 - 3.630
Beta	1.21
RSI	53.66
Earnings Date	Aug 22, 2025

About Zhaoke Ophthalmology

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People’s Republic of China, South Korea, and Hong Kong. It is developing various drugs that cover ophthalmic indications, including dry eye, myopia, presbyopia, wet age-related macular degeneration, diabetic macular edema, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 294
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6622

Financial Performance

In 2024, Zhaoke Ophthalmology's revenue was 69.32 million, an increase of 269.73% compared to the previous year's 18.75 million. Losses were -237.49 million, -38.32% less than in 2023.

Financial numbers in CNY